Pengbo

Pengbo Biopharma is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the discovery and development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The company utilizes its proprietary P-ADC platform, which focuses on site-specific conjugation and novel linker-payload systems to enhance the safety and efficacy of its therapeutic candidates. Its lead programs include PB-722, a Claudin 18.2-targeted ADC, and PB-711, a Trop-2-targeted ADC, both of which are currently undergoing clinical evaluation in patients with advanced solid tumors. By integrating advanced protein engineering with specialized chemistry, Pengbo Biopharma aims to deliver precision oncology treatments that overcome the limitations of existing therapies. The company is backed by prominent life science investors and maintains a robust research and development facility in the Suzhou Industrial Park.